AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33220115
Drug: Training stop‐smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training stop‐smoking practitioners to deliver support according to the NCSCT Standard Treatment Programme
Trial: 34620774
Drug: Social media-based
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social media-based community consultation (CC) using Facebook and Instagram advertisements
Trial: 32669234
Drug: Daily digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily digital media activity
Trial: 33886115
Drug: Single antibiotic
RxNorm normalized name: BACITRACIN ZINC 500 [iU] in 1 g TOPICAL OINTMENT [Single Antibiotic]
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single antibiotic
Trial: 32841892
Drug: Low-intensity interventions
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity interventions for individuals with low interpersonal risks and concurrent protective psychological factors
Trial: 32609084
Drug: Progesterone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (400 mg vaginal suppositories, twice daily)
Trial: 32609084
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched vaginal suppositories)
Trial: 32782170
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) for 3 months before IVF
Trial: 33107418
Drug: Δ9‐THC (1.19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ9‐THC (1.19 mg/2 ml)
Trial: 36502500
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% hexylresorcinol
Trial: 36502500
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% hydroquinone
Trial: 34418415
Drug: Lung ultrasound-guided
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung ultrasound-guided treatment strategy
Trial: 32962735
Drug: Mannose supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannose supplementation at a total of 1-2 g mannose/kg b.w./d divided into 5 single doses
Trial: 34083403
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg daily for 3 days followed by 250 mg daily for 12 days + Hydroxychloroquine 200 mg twice daily for 15 days
Trial: 32638409
Drug: Fasting proinsulin
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting proinsulin to insulin ratio
Trial: 33783846
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hypnosis and TENS
Trial: 32844813
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants (Type 1 ITI protocol)
Trial: 32844813
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants (Type 4 ITI protocol)
Trial: 34421796
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of GTN (5 mg GTN in 50 ml saline at a rate of 0.4 mg/h for 12.5 h/day for 2 days)
Trial: 34421796
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.9% normal saline (NS) (total 50 ml/day at 4 ml/h for 12.5 h/day for 2 days)
Trial: 33256841
Drug: Immunosuppressants in
RxNorm normalized name: Other immunosuppressants in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressants in AS cohort
Trial: 35684140
Drug: High-dose eggshell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose eggshell membrane
Trial: 35684140
Drug: Low-dose eggshell
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose eggshell membrane
Trial: 34047177
Drug: 6TG added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6TG added to MTX/6MP maintenance therapy
Trial: 35659172
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy (PDC)
Trial: 34138468
Drug: IVIG (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (25 g/day for three days)
Trial: 32865577
Drug: Tele-BA (behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-BA (behavioral activation) treatment delivered by lay counselors
Trial: 32865577
Drug: Tele-PST (problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele-PST (problem-solving therapy) delivered by licensed clinicians
Trial: 34602412
Drug: Capsule Picolin
RxNorm normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Picolin (500 mg, two capsules thrice a day)
Trial: 34602412
Drug: Tablet Picolin-E
RxNorm normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Picolin-E (250 mg, thrice a day)
Trial: 34602412
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, twice a day)
Trial: 34602412
Drug: Capsule Picolin
RxNorm normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Picolin
Trial: 34602412
Drug: Tablet Picolin-E
RxNorm normalized name: Picolinic acid
DrugBank: Picolinic acid (DB05483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Picolin-E
Trial: 35439983
Drug: Nomogram incorporating
RxNorm normalized name: Liposome-incorporated DTP-GDP
DrugBank: Liposomal N-acetylglucosminyl-N-acetylmuramly-L-Ala-D-isoGln-L-Ala-gylceroldipalmitoyl (DB17316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram incorporating independent prognostic factors (age, AJCC 8th edition T, N and M stage, carcinoembryonic antigen (CEA), tumour differentiation, chemotherapy, perineural invasion, LNR)
Trial: 36307314
Drug: Qili Qiangxin
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qili Qiangxin Capsule combined with cardiac exercise rehabilitation
Trial: 34443468
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with hydrolyzed fish cartilage for 90 days
Trial: 35427193
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control group (n = 114)
Trial: 34304292
Drug: Home-based strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based strength exercise (twice weekly for 10 weeks)
Trial: 32770612
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus gabapentin titrated to drug tolerance during radiation
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination strategy (including at least two blood pressure lowering agents plus a statin, with or without aspirin)
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination strategy (with aspirin)
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination strategy (without aspirin)
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination strategy
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination strategy with aspirin
Trial: 34469765
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination treatment
Trial: 34521398
Drug: Curcumin nanomicelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin nanomicelle capsules 80 mg twice a day for 7 weeks
Trial: 32101271
Drug: Olanzapine and
RxNorm normalized name: olanzapine and samidorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine and sertraline
Trial: 32101271
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and sertraline
Trial: 34996948
Drug: MCALP group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCALP group: 0.5 g of methylprednisolone intravenously for three consecutive days at the beginning of the course and 3rd month, oral prednisone at a dose of 15 mg every other day for 6 months
Trial: 34996948
Drug: FP group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP group: 0.8-1.0 mg/kg/days of prednisone (maximum 70 mg/day) for 2 months, then tapered by 5 mg every 10 days for the next 4 months
Trial: 32819927
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12 (1 mg/day in weeks 1-8, 1 mg/week in weeks 9-52)
Trial: 32819927
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin B12 (1 mg on alternate days in weeks 1-2, 1 mg/week in weeks 3-8, 1 mg/month in weeks 9-52)
Trial: 32819927
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B12
Trial: 32819927
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin B12
Trial: 34626927
Drug: LB 266
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LB 266 mg TAP block alone
Trial: 34626927
Drug: ITM 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITM 50 μg followed by LB 266 mg TAP block
Trial: 34626927
Drug: ITM 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITM 150 μg alone
Trial: 34626927
Drug: LB 266
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LB 266 mg TAP block alone and LB + ITM group
Trial: 33248594
Drug: HL group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL group (high-low Zn, basal diets supplemented 120 mg/kg Zn)
Trial: 33248594
Drug: LH group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH group (low-high Zn, basal diets supplemented 120 mg/kg Zn)
Trial: 34282267
Drug: Mecobalamin intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecobalamin intramuscular injections (0.5 mg/day, 3 times/week)
Trial: 34282267
Drug: Mecobalamin oral
RxNorm normalized name: mecobalamin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecobalamin oral tablets (1.5 mg/day)
Trial: 36432469
Drug: P-CHO (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-CHO (20 g of Pronativ®, native whey protein and 60 g of carbohydrate)
Trial: 36432469
Drug: CHO (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (80 g of carbohydrate)
Trial: 33691305
Drug: Other drug
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drug classes
Trial: 32469384
Drug: Savolitinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib (600 mg orally once daily)
Trial: 32469384
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks without treatment)
Trial: 32243609
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg daily oral iron
Trial: 35811090
Drug: Vestibular socket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular socket therapy (VST) (test; n=20)
Trial: 35811090
Drug: Contour augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contour augmentation (control; n=20)
Trial: 32476816
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears and 0.1% fluorometholone eye drops three times a day (G-DESOS group)
Trial: 33273644
Drug: Sufentanyl target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanyl target infusion based on the pupillary pain index
Trial: 33273644
Drug: Standard sufentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sufentanyl target infusion left to the discretion of the anesthesiologist (Control)
Trial: 34083348
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (home-based exercise, weekly telephone support, breathlessness management leaflet) with either placebo or active NMES for 6 weeks
Trial: 32588429
Drug: Non-platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based chemotherapy (non-PBC)
Trial: 32588429
Drug: PBC in
RxNorm normalized name: Brovex PBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBC in first-line therapy
Trial: 34717535
Drug: Paracetamol 1 g
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g (P group)
Trial: 34717535
Drug: Dexamethasone 8 mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8 mg IVI (D group)
Trial: 32964807
Drug: Docking studies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docking studies (new designed compound C2)
Trial: 33956703
Drug: Pramipexole (n=31),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (n=31), initiated at 0.125 mg 2 times a day, increased to a target of 4.5 mg/d
Trial: 34726501
Drug: Banaba (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banaba (500 mg) twice a day for 12 weeks
Trial: 35553855
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained daily lifestyle without training)
Trial: 32418078
Drug: Adjuvant transarterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant transarterial infusion chemotherapy (TAI) with FOLFOX regimen
Trial: 32418078
Drug: Follow-up without
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up without any adjuvant treatment (FU group)
Trial: 36573717
Drug: Glimepiride treatment
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride treatment
Trial: 32107337
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2) given concurrently prior to each infusional EPOCH cycle
Trial: 32107337
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2) given sequentially (weekly for 6 weeks) following completion of EPOCH
Trial: 32107337
Drug: EPOCH chemotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH chemotherapy (96-hour IV infusion of etoposide, doxorubicin, vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles)
Trial: 32713846
Drug: Colonoscopy (CC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonoscopy (CC), n=346
Trial: 32713846
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy (CE), n=305
Trial: 33399050
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RT) with Gloreha device
Trial: 36124455
Drug: Acupotomy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy treatment on pain points around knee joint, once a week for 3 weeks.
Trial: 36124455
Drug: Celecoxib capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib capsule, 200 mg orally once a day for 3 weeks (western medicine group).
Trial: 33236043
Drug: Peanut group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut group (56 g/d as snacks, n=113)
Trial: 34085476
Drug: Valaciclovir hydrochloride
RxNorm normalized name: Valaciclovir hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir hydrochloride tablets, mecobalamin tablets, and vitamin B1 tablets
Trial: 34738660
Drug: Romosozumab (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (210 mg sc monthly, n = 17)
Trial: 34738660
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg sc daily, n = 19)
Trial: 34738660
Drug: Placebo (sc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sc monthly, n = 20)
Trial: 35645797
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg)
Trial: 35645797
Drug: Palonosetron (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (75 μg)
Trial: 32797298
Drug: rt-PA (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (intravenous recombinant tissue-plasminogen activator)
Trial: 34351478
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase
Trial: 33729386
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with batroxobin
Trial: 32854478
Drug: miR‐146a‐3p inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miR‐146a‐3p inhibitor group
Trial: 32854478
Drug: sh‐KCNQ1OT1+miR‐146a‐3p inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sh‐KCNQ1OT1+miR‐146a‐3p inhibitor group
Trial: 32208848
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice (200-500 mL/day)
Trial: 32208848
Drug: Resveratrol (150-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (150-1000 mg/day)
Trial: 34279759
Drug: Group Cognitive-Behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive-Behavioral Intervention (Healthy Minds) consisting of eight sessions based on cognitive behavioral therapy principles and techniques.
Trial: 33599062
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections every month for a maximum of two sessions
Trial: 33940637
Drug: Fast needle
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast needle acceleration (higher than 1 g)
Trial: 33940637
Drug: Slow needle
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow needle acceleration (lower than 1 g)
Trial: 33448941
Drug: Air-Fluidized Therapy
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-Fluidized Therapy (AFT)
Trial: 36909343
Drug: Prebiotic supplement
RxNorm normalized name: FlorastorSelect Gut Boost Daily Probiotic and Prebiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic supplement
Trial: 35710539
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication reduction
Trial: 34101780
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 1.2 mg/d + vitamin B12 50 μg/d
Trial: 32858346
Drug: Trazodone 50
RxNorm normalized name: traZODone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50 mg/d (TRAZ)
Trial: 35165100
Drug: Sunitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib treatment
Trial: 36216827
Drug: Anti-angiogenic adjuvant
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenic adjuvant therapy
Trial: 35297582
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group B (100 kV, 100 mA)
Trial: 35297582
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group C (100 kV, 50 mA)
Trial: 35297582
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group D (80 kV, 100 mA)
Trial: 35297582
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group E (80 kV, 50 mA)
Trial: 32164877
Drug: 131I-metuximab (27.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I-metuximab (27.75 MBq/kg) administered as a single transarterial injection 4-6 weeks after hepatectomy
Trial: 32881138
Drug: 600 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/kg ALA
Trial: 33674241
Drug: Add-on self-care
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-on self-care therapy education